# Alliance A212102: blinded reference set for multi-cancer detection tests

Source: https://onco.cc/trials/alliance-a212102-mced-reference-set/  
OnCo record `alliance-a212102-mced-reference-set` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A National Cancer Institute effort to build a shared, blinded bank of blood samples so different multi-cancer tests can be checked on the same people.

## Summary

Alliance A212102: blinded reference set for multi-cancer detection tests (NCT05334069) is an observational study sponsored by Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI). It collects blood and tissue samples from people with and without cancer to evaluate tests for early cancer detection; the official title is a blinded reference set for multicancer early detection blood tests.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,900 participants, a start on 18 August 2022 and primary completion expected on 31 January 2027.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: A212102
- Registry id: NCT05334069
- Phase: observational
- Setting: People with and without cancer across more than 700 US sites, giving blood and tissue to build a blinded specimen set on which companies' multi-cancer tests can be compared
- Sponsor: Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Enrolled: 2900

## Sources

- ClinicalTrials.gov NCT05334069: https://clinicaltrials.gov/study/NCT05334069

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/alliance-a212102-mced-reference-set.json